MYC and angiosarcoma: Is dosage compensation to the same supraphysiological Myc level in Myc-WT;p53KO and Myc+/−;p53KO tumors a feature unique to hemangiosarcomas, or do other tumors arising in this setting also demand supraphysiological Myc levels?